Long-term clinical and magnetic resonance imaging follow-up of dogs with osseous-associated cervical spondylomyelopathy

对患有骨性颈椎脊髓病的犬进行长期临床和磁共振成像随访

阅读:2

Abstract

BACKGROUND: Osseous-associated cervical spondylomyelopathy (OA-CSM) is a complex disorder with limited long-term survival. The longitudinal progression is currently unknown. OBJECTIVE: To describe changes on magnetic resonance imaging (MRI) over a 2-year minimum period. We hypothesized that spinal lesions would progress in the majority of dogs. ANIMALS: Eleven dogs previously diagnosed with OA-CSM were prospectively studied. Nine dogs were treated medically, whereas 2 were treated surgically. METHODS: Clinical and MRI follow-up were performed with a median time between MRI studies of 30 months (range, 24-54). Morphologic assessment evaluated vertebral canal stenosis, spinal cord compression, foraminal stenosis, and articular processes, among other variables. Morphometric assessment included vertebral canal area, spinal cord area, area of the articular processes, and foraminal height. RESULTS: On follow-up MRI, the most affected site at the initial examination in medically treated dogs had progressed in 4 of 9 dogs, improved in 4, and was unchanged in 3. Clinically, all dogs except 2 medically treated dogs were unchanged to improve at follow-up. Initially, 50 of 60 (83.3%) intervertebral spaces had vertebral canal stenosis, whereas in the follow-up MRI 82.3% did. Of the sites with stenosis, 45.7% were unchanged, 18.6% improved, and 38.9% worsened. Morphometry identified significant decreases in vertebral canal and spinal cord areas at C4-C5 through C6-C7, and significant progression of articular process irregularities at C3-C4 and C6-C7. CONCLUSIONS AND CLINICAL IMPORTANCE: This long-term follow-up study of dogs with OA-CSM did not identify clinical or MRI progression of lesions in the majority of dogs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。